NAS
BCRX icon

Nykredit A/S’s BioCryst Pharmaceuticals BCRX Stock Holding History

Nykredit A/S’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$26.9K Buy
+2,688
New +$24.3K ﹤0.01% 1648

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $12.8B AUM 48.82% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Nykredit A/S's BCRX Position: Q2 2026 in Review

Nykredit A/S opened a new position in BioCryst Pharmaceuticals (BCRX) in Q2 2026: 2,688 shares worth $26.9K. The stake represents ﹤0.01% of the portfolio and ranks #1648 among its holdings.

223 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • Nykredit A/S held 2,688 shares of BioCryst Pharmaceuticals worth $26.9K as of Q2 2026.
  • BioCryst Pharmaceuticals was a new Nykredit A/S position in Q2 2026.
  • BioCryst Pharmaceuticals made up ﹤0.01% of Nykredit A/S's portfolio in Q2 2026, its #1648 holding.
  • 223 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Nykredit A/S's 13F filing for Q2 2026, filed 13 Aug 2026.